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The enormity and complexity of cancer genome data present significant challenges in downstream validation
of novel oncogenes and tumor suppressors. In this issue of Cancer Cell, Hu et al. evaluate candidate onco-
genes in a recurrent amplification in poor-prognosis breast cancers. They identify and validate the prometa-
static gene metadherin (MTDH) as a key modulator of endothelial adhesion and chemoresistance.Metastasis is a complex process involving
at least four critical steps: extravasation of
primary cancer cells into vasculature or
lymphatics; survival of such cells in the
circulation; intravasation and seeding in
a new organ; and finally, growth in this
new tissue microenvironment into a
metastatic tumor (Gupta and Massague´,
2006). At eachstep, the aspiringmetastatic
cancer cell faces multiple obstacles, each
of which is overcome with underlying
epigenetic, genetic, and genomic alter-
ations thatmodify the expressionand func-
tion of specific metastasis-relevant genes.
Based on expression profile changes,
Massague´ and colleagues have elegantly
identified and validated four prometastasis
genes—EREG,MMP1,MMP2, and COX2,
which function to enhance extravasation—
in both tail vein injection and orthotopic
assays in immunodeficient mice (Gupta
et al., 2007; Minn et al., 2005). Utilizing
cross-species genomic comparisons,
NEDD9 was identified as the target of
recurrent amplification in human and
mouse metastatic melanomas with
progression-correlated protein expression
(Kim et al., 2006). Mechanistically, NEDD9
exerts proinvasive and metastatic activity
in vitro and in vivo (Kim et al., 2006) and
mediates the RAC1-dependent switch
fromamoeboid tomesenchymalcellmove-
ment, a feature of epithelial-to-mesen-
chymal transition (Sanz-Moreno et al.,
2008). Thus, these and other examples
have validated the utility of oncogenomics
for the discovery of metastasis genes.
In this issue of Cancer Cell, Hu et al.
(2009) provide evidence that the gene
metadherin (MTDH) drives one of the
steps critical for breast cancer metastasis
to the lungs: adhesion to thewalls of bloodvessels. Using ACE (analysis of CNAs
by expression data), a nearest-neighbor
analysis of gene expression data, a
minimal 2.9 Mb piece of chromosome 8
was found to be recurrently amplified in
poor-prognosis breast cancers, a finding
confirmed with fluorescence in situ
hybridization (FISH) analysis. Of six genes
examined in this region, only the enforced
expression ofMTDH, also known asAEG1
(astrocyte-elevated gene 1), resulted in
increased lung seeding after tail vein injec-
tion of themildlymetastaticMDA-MB-231
cell line. Conversely, knockdownofMTDH
in the metastatic MDA-MB-231 derivative
line LM2 decreased lung seeding, con-
firming previous studies performed in
4T1 breast cancer cells (Brown and
Ruoslahti, 2004). MTDH overexpression
had minimal effect on bone and brain
metastases, suggesting tissue specificity.
Metastasis genes can impact the
process via enhancing one or more steps
in a highly complex cascade of biological
processes. The authors eliminated a role
forMTDH in intravasation or extravasation
using both in vitro and in vivo assays.
Instead, MTDH overexpression was
shown to enhance breast cancer cell
adhesion to lung endothelial cells in an
in vitro attachment assay, while knock-
down produced the opposite effect in
three independent breast cancer cell lines.
Conceptually, this enhanced adhesion
could lead to increased deposition of
cancer cells in the lung, providing a statis-
tically higher likelihood that deposited
cellswill bloom into overtmetastases (Fig-
ure 1). Indeed, a previous study showed
a higher colocalization of MTDH-positive
metastatic cells with lung endothelial cells
(Brown and Ruoslahti, 2004).Cancer CHu et al. also demonstrate an effect of
MTDH on chemoresistance. Overexpres-
sion decreased and knockdown sensitized
breast cancer cells to cell killing by pacli-
taxel, doxorubicin, cisplatin, and hydrogen
peroxide in vitro. Again, multiple cell lines
showed this effect, demonstrating the
general function of MTDH in chemoresist-
ance. These results were extended to an
in vivo subcutaneous tumor assay for
both paclitaxel and doxorubicin. By using
overexpression and knockdown assays,
the effect on chemoresistance was shown
to be partially mediated by ALDH3A1 and
MET, two genes whose expression levels
were significantly altered by modulation of
MTDH. Thus, in a clinical context, cells
with increased MTDH levels could be
positively selected for during a course
of chemotherapy. This microevolutionary
stress, along with selection for other
factors, could iteratively refine the primary
and/or circulating tumor cells for full meta-
staticpropensity (Figure1). Importantly,Hu
et al. connected MTDH to human patient
data, showing that MTDH amplification/
overexpression correlates with breast
cancer patient survival independently of
several classical risk factors such as ER
negativity or HER2/neu positivity.
The Hu et al. study contains many of the
requisite steps requiredofa rigorouscandi-
date gene validation effort, namely: (1) the
use of multiple cell lines to demonstrate
functional activities, ensuring that the
observed consequences are not artifacts
of a particular cell line; (2)mutually reinforc-
ing and complementary functional data,
i.e., reciprocal overexpression and knock-
down data; (3) use of multiple model
systems, including in vitro and in vivo
assays; (4) examination of DNA, RNA, andell 15, January 6, 2009 ª2009 Elsevier Inc. 1
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regulation; (5) explorationofputativedown-
stream effectors; and (6) establishment of
relevance to human tumor specimens.
Such a multipronged, stringent approach
is necessary for establishing the biological
relevance of a novel cancer gene if such
studies are to advance the field.
The Hu et al. study also highlights a key
challenge in cancer genomics. The
proverbial haystack of candidate genes
has grown exponentially in the era of
large-scale cancer genomics. The search
for needles—those novel cancer genes
that will lead to new therapeutics and
diagnostics for cancer patients—has thus
become ever more daunting. Rigorous
validation and mechanistic exploration
of a single genetic element of interest
(GEOI), as in this study and elaborated
elsewhere (Chin and Gray, 2008), is time
and labor intensive, representing a major
bottleneck. Rapid translation of a novel
target or molecular diagnostic to the clinic
therefore demands that the cancer
research community be equipped and
ready to prioritize and focus its resources
on the highest potential candidates.
Here, we need to employ high-throughput
biological assays or functional genomic
screens that can systematically evaluate
many GEOIs in a single experiment so
that the cancer relevance of a GEOI can
be assigned based on not only the
genomic and genetic but also the biolog-
ical weight of evidence.
In designing functional genomic
screens, one shouldbemindful that cancer
is a multigenic disease that evolves in
a hostmicroenvironment and that nosingle
model is capable of fully recapitulating the
complex biology of cancer in a human
patient. For example, the ‘‘experimental
metastasis’’ assay involving forcibly inject-
ing cancer cells into the tail vein to look for
lung colonization is commonly used as
a proxy of metastasis; however, in reality
this captures only one late aspect of this
complex cascade. Similarly, in vitro inva-
sion assays in modified Boyden chambers
assess only the ability of a cancer cell to
leave the primary tumor site and invade
into the surrounding microenvironment,
not its ability to enter the circulation or to
grow in a foreign soil. Mutually reinforcing
data from both models, against the back-
drop of genomic and correlative data in
human cancers, will increase our confi-
dence in the biological relevance of any
given GEOI. In other words, we should
recognize that each model has pros and
cons, and that such limitations necessitate
the complementary uses of disparate
models. Thus, wemust invest in the devel-
opment and characterization of compre-
hensive experimental model systems that
canbeused to simulate thediverse genetic
and cellular contexts in which cancer
evolves to enable informative functional
genomic screens.
In summary, the studies of Hu et al.
provide another strong testament to the
power of a comprehensive atlas of the
genomicarchitecture of cancer topinpoint
novel genes critical to the development
and progression of lethal cancers. At the
same time, they underscore the need for
high-throughput functional genomic
screens and reinforce the importance of
multiple in vitro and in vivomodel systems
for translating insights from large-scale
cancer genomics.
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Figure 1. Dual Role of MTDH in Breast Cancer Chemoresistance and Endothelial Adhesion
Amplification of 8q22 or overexpression of metadherin (MTDH) by other means results in a breast cancer
cell that is both more resistant to chemotherapy and more adhesive to blood vessels lining the lung. This
one-two punch could explain a higher rate of metastasis in patients withMTDH-overexpressing cells. The
lung illustration is in the public domain and was retrieved from http://commons.wikimedia.org/wiki/
Image:Respiratory_system_complete_en.svg.
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